ABSTRACT
Epidemiological data have demonstrated that the prevalence of either obesity or hepatocellular carcinoma (HCC) is increasing worldwide during past decades, and obesity has been unequivocally shown to be a risk factor for HCC. It has been reported that a significant proportion of HCC in obesity develops in cryptogenic cirrhosis, which is largely associated with the progression of nonalcoholic fatty liver disease, especially nonalcoholic steatohepatitis. Since the HCC is a highly malignant tumor with a poor prognosis, a better understanding of the molecular mechanisms may help researchers to explore new approaches for preventing and treating the obesity-related HCC, and thereby facilitating a substantial reduction of morbidity and mortality. In this article, we reviewed the mechanisms underlying the relationship between obesity and HCC, with an emphasis on the roles of insulin/insulinlike growth factor axis, adipose tissue derived hormones, oxidative stress, and liver stem cells. In addition, we will discuss the impact of life-style modification on obesityrelated HCC.
INTRODUCTION
The World Health Organization (WHO) estimated that more than 1.5 billion adults (20 years or older) worldwide are overweight and of whom over 500 million people are obese, as defined by the body mass index (BMI) equal or greater than 25 or 30 kg/m 2 , respectively.(1) Obesity is a part of the metabolic syndrome which includes several other conditions such as hypertension, stroke, type 2 diabetes (T2DM), dyslipidemia and nonalcoholic fatty liver disease (NAFLD). Epidemiological evidence over the recent years has demonstrated that obesity is a risk factor for the development of many cancers such as those derived from endometria, prostate, postmenopausal breast, kidney, colon, pancreas, esophagus, and liver.(2-12) Many factors altered in obesity are considered important for causing obesityassociated cancers. These factors include increased blood levels of insulin, insulin-like growth factors (IGFs), leptin, interleukin (IL)-6, IL-17, tumor necrosis factor-alpha (TNF-alpha) and decreased adiponectin. (13) (14) (15) (16) (17) This review focuses on the relationship between obesity and hepatocellular carcinoma (HCC), with an emphasis on the molecular mechanisms by which obesity predisposes to HCC, as well as the effect of lifestyle modification on preventing HCC in obese people.
EPIDEMIOLOGICAL EVIDENCE LINKING OBESITY AND HCC
HCC is the fifth most frequent malignancy, with an incidence rate of 10.8/100,000 and a mortality rate of 10/100,000 worldwide.(18) China is the high prevalence area for HCC, accounting for approximately 55% of all cases worldwide. (19) The incidence of HCC is constantly rising in many western countries, including USA, United Kingdom, Australia, and France. (20) (21) (22) (23) Although the risk factors for most HCC cases are well established (HBV and HCV infection, and alcohol intake), in 5-30% of HCC cases the etiological factors are not readily identifiable. (24) In parallel with the rising HCC incidence, the prevalence of obesity has been increasing markedly over the past few decades. In a cohort study involving 362,552 Swedish men,(10) the relative risk for HCC in obese individuals (BMI>30 kg/m 2 ) was 3.1 fold higher than that in people with normal weight. A positive dose-response pattern of higher liver cancer risk with increasing BMI was observed. In a study conducted in 23,820 resident Taiwanese, (25) those with obesity (BMI>30 kg/m 2 ) was independently associated with a 4.13 times higher in HCC risk if they are HCV infected, and 2.36 times higher in HCC risk if they are without HBV or HCV infection, suggesting a synergistic oncogenic effect between obesity and HCV infection. It was also estimated that the synergistic effects of obesity, diabetes and HBV or HCV infection result in a 100-fold increase in the risk of HCC development. (25) HCC in obese subjects is associated with increased mortality. In a 16-year follow-up study of more than 900,000 U.S. adults, the risk of cancer-related death from liver cancer was 4.52 times higher for severe obese men (BMI≥35kg/m 2 ) than subjects with normal weight (BMI 18.5-24.9 kg/m 2 ).(5) All these data suggest that obesity affects the incidence and mortality of HCC.
It is unclear why obese subjects are more susceptible to develop HCC. It was reported that a higher incidence of HCC frequently occurred in obese patients with cryptogenic or alcoholic cirrhosis. (26) (27) (28) In a study conducted in USA involving 105 consecutive patients with HCC,(29) HCV infection and cryptogenic cirrhosis are the two commonest causes of HCC (51% and 29%, respectively). Clinically, cryptogenic cirrhosis is largely attributed to the presence of NAFLD, in particular, nonalcoholic steatohepatitis (NASH), (27, (29) (30) ) the more aggressive form of NAFLD. NAFLD is now believed to be the most common cause of abnormal liver function tests in clinical setting. The causal relation between NASH and HCC has been reported both epidemiologically and experimentally.(31-36) Most obese people have abnormal livers one way or another. For example, it was reported that approximately 60% of patients with NAFLD have simple steatosis, 25% have NASH, and 3%-5% have cirrhosis, whereas only 10%-15% of obese patients are expected to have normal livers.(37) On the other hand, 30%-100% NAFLD subjects are believed to have obesity. It has been reported that HCC occurs in 0.5% patients with NAFLD and up to 2.8% of patients with NASH.(38-39) The histological evidence of NASH was found to be present in 20% of patients with cryptogenic cirrhosis 4.3±1.6 years prior to the diagnosis of HCC. (29) In a cross-sectional multicenter study in Japan, obesity (defined as BMI≥25 kg/m 2 ) was present in 62% of 87 patients with histologically proven NASH who developed HCC.(32) Clearly, obesity and NASH are closely linked with HCC. Indeed, progression from NASH to HCC has also been recapitulated in mice fed on a choline-deficient L-amino acid-defined (CDAA) diet for 84 weeks. (40) Apparently, increased epidemic of obesity in general population may increase the proportion of patients with both NASH and cryptogenic cirrhosis and may thus be responsible for higher incidence of HCC.
UNDERLYING MOLECULAR MECHANISMS LINKING OBESITY AND HCC
The possible molecular mechanisms underlying obesity-associated HCC as we discussed in this review article that were briefly summarized in Figure 1. 
Role of Insulin/IGF axis in obesity-related HCC
IGFs, including IGF-I and IGF-II, are the polypeptides structurally homologous to insulin. They are mainly synthesized and secreted by the liver in response to growth hormone (GH). . Possible molecular mechanisms in obesity-related HCC. Obesity leads to enhanced oxidative stress, increased insulin/insulin-like growth factor (IGF-II) production and aberrant adipokines secretion. The products of oxidative stress such as 8-hydroxydeoxy guanosine (OH8dG), 8-nitrogunanin and malondiadlehyde (MDA)-DNA adducts can initiate carcinogenesis due to their ability to damage DNA and biomembrane. Reactive oxygen species (ROS) induced calcium release can activate protein kinase C (PKC), and disrupt association of Kelch ECH associating protein 1 (Keap 1) and nuclear factor erythroid 2-related factor 2 (Nrf2). ROS can also activate transcription factor activator protein 1 (AP-1) through c-Jun NH2-terminal kinase (JNK)/p38 mitogen activated protein kinase (MAPK) pathway. In addition, ROS can lead to activation of nuclear factor kappa B (NF-kappa B) and hypoxia-inducible factors (HIFs). All these factors (i.e. PKC, Nrf2, NF-kappa B and HIFs) can regulate specific gene transcription associated with cell proliferation or apoptosis. Binding of free insulin-like growth factor II (IGF-II) to insulin growth factor-I receptor (IGF-IR) can stimulate carcinogenesis through phosphoinositide 3-kinase (PI3K/Akt) pathway or MAPK pathway. IGF-II can also stimulate insulin receptor (IR)-mediated signaling. Tissue inhibitor of metalloproteinase 1 (TIMP-1) is able to reduce matrix metalloproteinases (MMP)-mediated proteolysis of insulin growth factor binding protein 3 (IGFBP-3), leading to an increased production of free IGF-II. Leptin and adiponectin exert seemingly "opposite" functions in HCC development. Leptin can enhance cell proliferation through activation of Janus kinase (JAK)/signal transducer and activator of transcription 3 (STAT3), PI3K/Akt, and extracellular signal-regulated kinase (ERK) signaling pathways. In contrast, adiponectin can suppress tumor growth and increase cell apoptosis through tuberous sclerosis complex 2 (TSC2)/mammalian target of rapamycin (mTOR) pathway or JNK/caspase 3 pathway, as a result of phosphorylation of 5'-adenosine monophosphate activated protein kinase (AMPK). Adiponectin can also affect the role of leptin by inhibiting activation of STAT3 or Akt, as well as by increasing the expression of suppressor of cytokine signaling 3 (SOCS3). These pathways also modulate cyclin D1-dependent cell cycle transition.
Possible role of insulin/IGF axis in HCC
Insulin resistance (IR) is a key mechanism in the development of obesity, and hyperinsulinemia is frequently present in individuals with excessive body weight. In addition to its effects on metabolic homeostasis, insulin can act as a crucial mitogen that may result in carcinogenesis and metastasis of several cancers. One cohort study has indicated that fasting hyperinsulinemia not only signifies a poorer prognosis in the early stage of HCC, but also indicates a higher recurrence rate in the curative HCC.(50) Mice with obesity and T2DM are often associated with IR, and a higher incidence of HCC in these mice has been reported. Angiogenesis is an important mechanism in HCC development. IGF-II has been showed to facilitate angiogenesis as it could induce the synthesis of vascular endothelial growth factor (VEGF),(66) thereby favoring tumor formation and development. In addition, in vitro experiments in HCC cell lines have showed that the hypoxia environment may stimulate the production of IGF-II, which can enhance the DNA binding activity of transcription factor Egr-1 on the IGF-II P3 promoter. (67) Clinically, a higher level of plasma IGF-II could predict the occurrence of metastatic HCC after transcatheter arterial chemoembolization (TACE). (68) The mitogenic role of IGFs in the development of HCC may be partially attributed to the reduced production of IGFBPs. Significant down-regulation of IGFBP-1, -2, -3, and -4 expressions was detected in human HCC. (63, (69) (70) (71) (72) The reduced level of IGFBPs may substantially potentiate an increased bioavailability of IGFs. In particular, reduced expression of IGFBP-3 in HCC, possibly as a result of promoter hypermethylation, (70) is significantly associated with higher portal venous invasion and poorer prognosis. (73) To further support these observations, it was found that treatment of HCC cells with IGFBP-3 in vitro significantly prevents cell proliferation, which is associated with reduced IGF-I mitogenic activity and decreased expression of IGF-IR downstream effectors such as MAPK, Elk-1, Akt-1 and PI3K. (63) IGFs may be interacting with some other molecules to facilitate HCC development. Tissue inhibitor of metalloproteinase 1 (TIMP-1) is an inhibitor of matrix metalloproteinases (MMP) and its expression was found to be down-regulated in HCC. Leptin is an adipose-derived hormone encoded by ob gene. Subjects with overweight or obesity tend to have an increased production of leptin. It regulates body weight and metabolic homeostasis by controlling appetite and energy expenditure. (81) (82) Leptin is also involved in other biological processes such as hematopoiesis, (83) inflammation/immunity, (84) osteogenesis,(85) cell proliferation (86) and tissue angiogenesis.(87) Binding of leptin to its receptor triggers a cascade of signal events through activation of different signaling pathways, including cell proliferation, cell survival, and differentiation. However, not all receptors are functional in the leptin signaling. Among the six isoforms of leptin receptor (obRa-f) that have been identified so far, only the obRb isoform with long intracellular domain mediates intracellular signals. (88) Many in vitro studies have reported that leptin can regulate HCC growth by influencing cell proliferation and apoptosis. Leptin increases proliferation of human HCC cells through concomitant activation of Janus kinase (JAK)/signal transducer and activator of transcription (STAT), PI3K/Akt, and extracellular signal-regulated kinase (ERK) signaling pathways. (89) On the other hand, inhibition of these pathways effectively blocks leptinmediated invasion and migration of HCC cells. (89) The pro-proliferative role of leptin may be through its acceleration on the cyclin D1-mediated cell cycle progression in human HCC cells, as inhibitors specific for JAK2, PI3K/Akt, and mitogen-activated protein kinase kinase (MEK)/ERK1/2 can block this progression. (90) In addition to the above mechanisms, the proliferative effect of leptin was reported to be related to promotion of DNA synthesis and enhancement of mitotic activity, leading to increased HCC cells progressing to G2-M phase of the cell cycle. (91) Apart from its pro-proliferation effect, leptin was shown to prevent HCC cells from transforming growth factor-beta (TGF-beta) 1 induced apoptosis, likely through attenuating the effect of pro-apoptotic gene Bax. (90) The possible role of leptin in the development of liver cancer may also be reflected by some published in vivo studies. In human HCC, the expression level of leptin/leptin receptor was found to be correlated to the extent of tumor angiogenesis. (92) (93) In animal studies, intact leptin signaling was found to be necessary in the natural course of chronic liver condition such as NASH. In Zucker rats, which are known to naturally carry leptin receptor mutation and thus lack leptin signaling, dietary induced NASH was not associated with liver fibrosis nor do these rats develop HCC.(94) These data imply that leptin/leptin receptor signaling may be necessary for the malignant transformation of hepatocytes.
Adiponectin
Adiponectin is an important protective adipocytokine that is abundantly expressed and secreted by visceral adipocytes. Apart from adipose tissue, liver cells are also responsible for adiponectin production. (95) (96) In circulation, adiponectin exists as three major isoforms: trimers, hexamers, and larger multimers (also known as high molecular weight complex).(97) Multimeric isoform appears to be the most active one that is responsible for many of the physiological functions of adiponectin. (98) (99) Three adiponectin receptor isoforms have been identified: AdipoR1, AdipoR2 and T-cadherin. These three receptors have distinct tissue distributions and binding of adiponectin to these receptors may activate different cellular functions through activating multiple signaling pathways. (100) (101) Clinical epidemiological data have showed a consistent inverse association between adiponectin and obesity-related disorders, such as T2DM, (102) During the development of HCC, leptin and adiponectin may function in a seemingly "opposite" manner. Adiponectin was shown to inhibit transition of HCC cells from G1 to S phase via decreasing cyclin D1 expression,(111) whereas leptin was found to stimulate the G2-M transition during cell cycle progression. Recent evidence indicate that adiponectin can inhibit leptininduced tumor growth by reducing STAT3 and Akt phosphorylation and increasing suppressor of cytokine signaling (SOCS3), a negative regulator of leptin signal transduction. (114) Collectively, increased production of leptin and decreased secretion of adiponectin during obesity may substantially predispose the obese individuals to develop HCC.
ROLE OF OXIDATIVE STRESS IN OBESITY ASSOCIATED HCC
Obesity is inevitably associated with systemic chronic oxidative stress.(115-116) Three mechanisms have been proposed for increased oxidative stress in obesity. Firstly, obesity increases the mechanical and metabolic loads on the myocardium, thus increasing myocardial oxygen consumption and production of reactive oxygen species (ROS) such as superoxide, hydroxyl radical and hydrogen peroxides from the increased mitochondria respiration.(117) Secondly, adipokines released by the adipose issues, such as TNF-alpha, IL-6, leptin, adiponectin, and resistin, have been documented to play roles in oxidative stress.(118-123) Lastly, increased lipid peroxidation is frequently present in nutritious obesity.
Hepatocarcinogenesis is a multistep process. Oxidative stress may play a vital role in the first two steps of carcinogenesis: initiation and promotion stages. In the initiation stage, the initiated mutated cells usually contain a fixation DNA mutation. ROS have been documented to cause DNA damage. The most abundant cellular product of oxidative damage is 8-hydroxydeoxy guanosine (OH8dG),(124) which can pair with cytosine or adenine to form G:A or G:C mismatch. If the mutagenic replication of OH8dG as templates, G→T substitutions would occurred, while if the OH8dG misincorporation as substrates, A→C substitutions would take place.(125) Similarly, reactive nitrogen species (RNS) can cause nitrative DNA damage to form 8-nitrogunanin which is a mutagenic DNA lesion, leading to G→T transversions. (126) Apart from causing DNA damage, free radicals also damage the cellular biomembranes, leading to lipid peroxidation. One of the major products of lipid peroxidation is malondiadlehyde (MDA), which reacts with several nucleic acid bases to form dG, dA, and dC adducts.(127) MDA-DNA adducts can induce mutations in oncogenes and tumor suppressor genes. In vitro studies have showed that MDA-DNA adduct levels correlate with altered cell cycle control in cultured cells. (128) The promotion stage is a reversible process characterized by the clonal expansion of initiated cells to form identifiable focal lesions. The expansion of initiated cells is mainly the result of enhanced cell proliferation and/or reduced apoptosis. ROS is involved in this stage through altering the structure or function of major transcription factors that are related to proliferation, migration, cell cycle progression, cell survival and cell death.
ROS promotes the proliferation of the initiated cells and thus favors tumor formation through several mechanisms. (1) ROS induces calcium release from intracellular compartments, resulting in the activation of kinases, such as protein kinase C (PKC). Active PKC has been well-documented to regulate a variety of cellular functions such as proliferation, cell cycle progression, cell differentiation, cytoskeletal organization, cell migration, and apoptosis.(129) (2) ROS can react with and change the conformation of Kelch ECH associating protein 1 (Keap 1), resulting the disruption of the interaction between Keap1 and nuclear factor erythroid 2-related factor 2 (Nrf2), and liberation of Nrf2. (130) (136) (4) ROS is a potent activator for nuclear factor kappa B (NF-kappa B),(137) a critical transcription factor involved in the regulation of cell survival, differentiation, inflammation, and growth. (138) Activation of NF-kappa B has been well-linked to carcinogenesis through mechanisms such as promotion of cell proliferation, invasion, and angiogenesis, as well as inhibition of apoptosis. (138) (5) ROS may stimulate the production of and activate hypoxia-inducible factors (HIFs),(139) thus favoring cancer formation via enhanced cell proliferation and angiogenesis.
ROLE OF LIVER STEM CELLS IN OBESITY RELATED HCC
Liver stem cell (LSC) represents a cell compartment, which has a bipotential plasticity that can differentiate into hepatocytes or bile duct epithelia.(140) Rodent oval cells or human progenitor cells are regarded as facultative LSC in most of the available data. This cell compartment predominantly locates in the peripheral branches of the biliary tree known as the Canals of Hering. (141) (142) (143) In addition, small hepatocytes,(144) marrow stem cells, (145) and embryonic stem cells (146) are also thought to be candidates for LSC. When liver undergoes severe injuries or hepatocyte replication is inhibited, the quiescent LSC is activated and participates in liver regeneration. (174) Recently, the liver oval cells have also been shown to differentiate into pancreatic endocrine hormone-producing cells, (175) (176) and these cells can synthesize and secrete insulin in response to glucose stimulation. (176) Future studies are required to clarify whether oval cell-derived insulin-producing cells in obesity-related disorders may increase the probability of hepatic oncogenesis due to increased production of insulin.
EFFECTS OF LIFESTYLE MODIFICATION ON PREVENTING OBESITY RELATED HCC
Obesity-related HCC mostly derives from NASH progression. It is of great importance that proper treatment for NASH may reduce the incidence of HCC. Weight loss by dietary intervention and physical exercise has been regarded as the first-line therapy for NASH. (177) A study performed by Suzuki et al examined the influence of lifestyle modification on improvement of serum alanine aminotransferase (ALT) levels in 348 patients with NAFLD after one or two years follow-up. (178) The results showed that weight loss (≥5%) with subsequent weight maintenance resulted in significant improvement and persistent normalization of serum ALT levels. (178) This relationship has been also concluded from a recent Korean cohort. (179) Hickman et al followed up 43 patients with chronic liver disease (including 10 subjects with clinically or histologically diagnosed NAFLD), of which 31 completed a 15 months diet and exercise intervention, to investigate the long-term effect of weight loss on liver biochemistry and serum insulin levels in obese patients with liver disease. They found that modest weight loss by an appropriate diet and exercise resulted in persistent improvements of serum ALT, insulin levels and quality of life. (180) Additionally, in another study by Hashizume et al, who observed 9 patients with HCC and one with intrahepatic cholangiocarcinoma in NASH. They found that none had HCC relapse after curative therapy, and that might be associated with weight loss by the active therapeutic intervention of nutritional care and physical exercise, indicating that weight loss may improve the prognosis of HCC in NASH.(181) Therefore, lifestyle modifications, mainly gradual weight loss, a low calorie diet, and aerobic exercise, are necessary to prevent the progression of NASH-related HCC.
CONCLUSIONS
Numerous studies have showed a strong association of obesity with increased risk of HCC. The increased prevalence of obesity in our society and increased incidence of HCC certainly warrant rigorous investigations on several critical questions: how obesity is causally linked to HCC? What intervention can be employed to reduce the fat toxicity on liver cells during obesity? Can HCC be prevented through dietary or other life style modification in obese individuals? Despite numerous studies being conducted over the last few decades, the molecular mechanisms underlying obesity-related HCC still remain to be fully elucidated. Only after a better understanding of the molecular mechanisms involved in the obesity-related carcinogenesis is fully clarified that more effective preventive or therapeutic approaches for HCC may be developed. 
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